MRSA Partnering 2007-2012


The MRSA Partnering 2007-2012 report provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies.

Top MRSA deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The MRSA Partnering  2007-2012 provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of MRSA partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors MRSA technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual MRSA deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report scope
MRSA Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to  MRSA trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:
Trends in  MRSA dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading  MRSA deals by value since 2007
In MRSA Partnering 2007-2012, the available deals are listed by:
Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

MRSA Partnering 2007-2012 provides the reader with the following key benefits:
In-depth understanding of MRSA deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 50 actual MRSA deals entered into by the world’s biopharma companies since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Published : July 2012                     No. of Pages : 100                          Price:US$995
Buy Now  
Table Of contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in MRSA partnering
2.1. Introduction
2.2.  MRSA partnering over the years
2.3. Bigpharma MRSA dealmaking activity
2.4.  MRSA partnering by deal type
2.5. MRSA partnering industry sector
2.6. MRSA partnering by stage of development
2.7. MRSA partnering by technology type
2.8. Disclosed financial deal terms for MRSA partnering
2.8.1  MRSA headline values
2.8.2 MRSA upfront payments
2.8.3  MRSA milestone payments
2.8.4  MRSA royalty rates

Chapter 3 – Leading MRSA deals
3.1. Introduction
3.2. Top  MRSA deals by value
3.3. Top  MRSA deals involving bigpharma

Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Figures

Comments

Post a Comment

Popular posts from this blog

MarketReportsOnline: Indonesia Rubber Industry Analysis

Image
MarketReportsOnline.com adds "Assessment of Indonesia's Rubber Industry Analysis 2015" report to its research store. The global market is currently in its fourth year of surplus of natural rubber. The excess supply situation has caused stocks to pile high and prices are falling steadily. It is expected that global surplus by the year 2020 will be approximately 1 million tons of natural rubber and 3 million tons of synthetic rubber.World demand for natural rubber, which is primarily used to manufacture tires, is cooling down due to the economic downturn in China. Asia accounts for 93% of the world natural rubber production with Thailand being the largest producer followed by Indonesia and Vietnam. Other large rubber producers in the region include India, China and Malaysia. Complete report available at http://www.marketreportsonline.com/442401.html .    China is the world’s largest consumer of natural rubber followed by India and the United States. In
Read more

Latest Guide to Chinese Pharmaceutical GMP Regulations

Image
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US$246 billion), an increase of 7.08 fold over 2000 level. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural will grow the Chinese drug market with a growth rate over 25 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015. Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which not only gave a fillip to the imported drugs from overseas pharmaceutical manufacturers but also attracted overseas investors to establish the foreign investment enterprises, including “Sino-foreign equity joint ventures (EJV)”,
Read more

Construction in Bahrain – Key Trends and Opportunities to 2015

Image
Synopsis This report provides detailed market analysis, information and insights into the Bahrain construction market, including: • Top level overview of the construction industry in Bahrain • Current, historic and forecast market value and trends of individual markets and categories supported by detailed descriptions of individual markets in the industry • Profiles of the top construction companies in Bahrain • Profiles of the ten largest construction projects in Bahrain Summary The Bahrain construction industry had been growing at a robust pace prior to the onset of the global financial crisis. This growth had been fuelled by the country’s long-term efforts to diversify its economy, efforts which have led to the emergence of Bahrain as the financial capital of the Middle East and have also led to many multinational companies establishing their Middle Eastern bases in the country, attracted by favorable tax policies and the country’s strategic location in the center of the Gulf
Read more